Denali Therapeutics Inc (DNLI)
20.52
+0.28
(+1.38%)
USD |
NASDAQ |
May 17, 16:00
20.52
0.00 (0.00%)
Pre-Market: 20:00
Denali Therapeutics Cash from Financing (TTM): 516.49M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 516.49M |
December 31, 2023 | 17.82M |
September 30, 2023 | 312.77M |
June 30, 2023 | 315.43M |
March 31, 2023 | 310.81M |
December 31, 2022 | 310.67M |
September 30, 2022 | 16.19M |
June 30, 2022 | 14.35M |
March 31, 2022 | 16.99M |
December 31, 2021 | 19.35M |
September 30, 2021 | 23.70M |
June 30, 2021 | 446.29M |
March 31, 2021 | 442.66M |
Date | Value |
---|---|
December 31, 2020 | 634.75M |
September 30, 2020 | 627.26M |
June 30, 2020 | 202.04M |
March 31, 2020 | 201.20M |
December 31, 2019 | 6.19M |
September 30, 2019 | 5.846M |
June 30, 2019 | 5.825M |
March 31, 2019 | 4.688M |
December 31, 2018 | 97.02M |
September 30, 2018 | 390.92M |
June 30, 2018 | 390.62M |
March 31, 2018 | 389.24M |
December 31, 2017 | 296.32M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
5.825M
Minimum
Jun 2019
634.75M
Maximum
Dec 2020
222.33M
Average
201.62M
Median
Cash from Financing (TTM) Benchmarks
Halozyme Therapeutics Inc | -243.86M |
AIM ImmunoTech Inc | 0.485M |
Perspective Therapeutics Inc | 167.19M |
Protalix BioTherapeutics Inc | 10.43M |
Armata Pharmaceuticals Inc | 59.32M |